DermBiont, Inc. Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
DermBiont, Inc. operates in biotechnology research with a focus on precision dermatology. The company develops targeted topical therapies aimed at the root causes of skin diseases, including small-molecule agents and microbiome-focused biotherapeutics. Its pipeline includes SM-020 for seborrheic keratosis, SM-030 for hyperpigmentation disorders, and DBI-001 and DBI-002 for atopic dermatitis, tinea pedis, and onychomycosis. Based in Boston, Massachusetts, the firm sits within the biotechnology industry and emphasizes dermatology-focused solutions. In 2021 it expanded its portfolio by acquiring Chromaderm, and in 2023 it added Daniel Yadegar to its board.